Clinical Trial Categories
  • Age & Physical Activity (1)
  • Alzheimer's Disease (7)
  • Arthritis (3)
  • Asthma (1)
  • Cancer - Bladder (1)
  • Cancer - Brain & CNS (16)
  • Cancer - Breast (8)
  • Cancer - Colon/Colorectal (2)
  • Cancer - Digestive System (2)
  • Cancer - Female Reproductive (8)
  • Cancer - Gastric (1)
  • Cancer - Kidney (2)
  • Cancer - Leukemia (6)
  • Cancer - Liver (1)
  • Cancer - Lung (3)
  • Cancer - Lymphoma (27)
  • Cancer - Melanoma (15)
  • Cancer - Mesothelioma (2)
  • Cancer - Myeloma (10)
  • Cancer - Other (5)
  • Cancer - Ovarian (2)
  • Cancer - Pancreas (2)
  • Cancer - Peritoneal (5)
  • Cancer - Prostate (12)
  • Cancer - Sarcoma (1)
  • Cancer - Stomach (1)
  • Cancer - Testicular (1)
  • Cancer - Tissue (6)
  • Crohn's Disease (3)
  • Dermatitis (2)
  • Dermatomyositis (1)
  • Healthy (6)
  • Hepatitis C (2)
  • HIV (4)
  • HPV (1)
  • Hypercholesterolemia (1)
  • Immune Disease - Autoimmune (9)
  • Immune Disease - Primary (2)
  • Immune Disease - Secondary (6)
  • Infectious Disease (2)
  • Inflammatory Disease (3)
  • Kidney Transplant (1)
  • Liver Disease (2)
  • Lupus Erythematosus (3)
  • Multiple Sclerosis (3)
  • Neurodegenerative (1)
  • OX40 (1)
  • Parkinson's Disease (1)
  • Pediatric (3)
  • Transplant (2)
Friday
May202016

NCT02800811

Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104

First-in-human, phase I, randomized, double-blind, placebo-controlled, single center study evaluating single and multiple ascending intravenous doses of FR104 in healthy subjects.

Condition: Healthy Volunteers
Sponsor: OSE Immunotherapeutics
Phase 1 

Relates to J Immunol. 2016 Dec 15;197(12):4593-4602. Epub 2016 Nov 14.

PrintView Printer Friendly Version